Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer
Trends in Endocrinology and Metabolism,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 1, 2025
Language: Английский
Systematic multi-omics investigation of androgen receptor driven gene expression and epigenetics changes in prostate cancer
Computers in Biology and Medicine,
Journal Year:
2025,
Volume and Issue:
189, P. 110000 - 110000
Published: March 8, 2025
Language: Английский
Regulation of Molecular Biomarkers Associated with the Progression of Prostate Cancer
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(8), P. 4171 - 4171
Published: April 10, 2024
Androgen
receptor
signaling
regulates
the
normal
and
pathological
growth
of
prostate.
In
particular,
survival
prostate
cancer
cells
is
initially
dependent
on
androgen
signaling.
Exposure
to
deprivation
therapy
leads
development
castration-resistant
cancer.
There
a
multitude
molecular
cellular
changes
that
occur
in
tumor
cells,
including
expression
neuroendocrine
features
various
biomarkers,
which
promotes
switch
androgen-independent
growth.
These
biomarkers
include
transcription
factors
(TP53,
REST,
BRN2,
INSM1,
c-Myc),
molecules
(PTEN,
Aurora
kinases,
retinoblastoma
suppressor,
calcium-binding
proteins),
receptors
(glucocorticoid,
receptor-variant
7),
among
others.
It
believed
genetic
modifications,
therapeutic
treatments,
microenvironment
are
contributing
progression
cancers
with
significant
heterogeneity
their
phenotypic
characteristics.
However,
it
not
well
understood
how
these
characteristics
modifications
arise
under
specific
treatment
conditions.
this
work,
we
summarize
some
most
important
associated
describe
involved
processes.
Language: Английский
Promising therapy for neuroendocrine prostate cancer: current status and future directions
Fei Xin,
No information about this author
Jia-Wei Xue,
No information about this author
Ji-zhongrong Wu
No information about this author
et al.
Therapeutic Advances in Medical Oncology,
Journal Year:
2024,
Volume and Issue:
16
Published: Jan. 1, 2024
Neuroendocrine
prostate
cancer
(NEPC)
is
a
highly
aggressive
variant
of
castration-resistant
cancer.
It
characterized
by
low
or
no
expression
the
androgen
receptor
(AR),
activation
AR-independent
signaling,
and
increased
neuroendocrine
phenotype.
Most
NEPC
induced
treatment
deprivation
therapy
pathway
inhibitors
(ARPIs).
Currently,
follows
strategy
for
small-cell
lung
cancer,
lacking
effective
drugs
specific
options.
This
review
summarizes
potential
novel
targets
therapies
treatment,
including
epigenetic
regulators
(zeste
homolog
2
inhibitors,
lysine-specific
demethylase
1
inhibitors),
aurora
kinase
A
poly-ADP-ribose
polymerase
delta-like
ligand
3
targeted
therapies,
combination
immunotherapies,
etc.
Other
promising
future
directions
are
also
discussed
in
this
review.
These
may
provide
new
opportunities
NEPC.
Language: Английский
Knockdown of USP7 alleviates atherosclerosis in ApoE-deficient mice by regulating EZH2 expression
Open Life Sciences,
Journal Year:
2024,
Volume and Issue:
19(1)
Published: Jan. 1, 2024
Atherosclerosis
(AS)
is
a
chronic
vascular
disease
associated
with
lipid
accumulation.
Understanding
the
molecular
mechanisms
of
AS
essential.
Ubiquitin-specific
protease
7
(USP7)
deubiquitination
enzyme
involved
in
various
cellular
processes,
including
metabolism.
In
this
study,
we
aimed
to
elucidate
role
USP7
progression
and
its
underlying
mechanism
using
ApoE-deficient
mice.
We
found
that
ablation
improved
morphological
characteristics
these
knockdown
reduced
inflammation,
evidenced
by
decreases
inflammatory
markers
IL-6,
TNF-α,
IL-1β
35,
40,
38%,
respectively
(
Language: Английский